截至发稿，华北制药市值为102亿元。 每经头条（nbdtoutiao）——与美元脱钩后，暴涨102倍，揭秘黄金疯涨背后神秘的"无形之手"！专家： 推动金价上涨的逻辑没有变 （记者 曾健辉） 每经AI快讯，华北制药（SH 600812，收盘价：5.94元）10月9日晚间发布公告称，截至本公告披露日， 公司及控股子公司对外担保总额约为17.01亿元，占2024年度经审计归属于上市公司普通股股东净资产 的31.56%，其中公司为控股子公司提供担保总额约为16.11亿元，占2024年度经审计归属于上市公司普 通股股东净资产的29.89%；对合并报表外单位担保金额为9000万元，占2024年度经审计归属于上市公 司普通股股东净资产的1.67%。 2025年1至6月份，华北制药的营业收入构成为：化学制剂药占比42.67%，化学原料药占比25.02%，生 物制剂占比16.71%，医药及其它物流贸易占比6.76%，医药中间体占比6.47%。 ...

传统疗法(如糖皮质激素、TCI等)安全性不佳，近十年来生物制剂和小分子靶向药等新兴产品逐渐涌 现，目前新兴疗法上市产品不多，全球范围内约十余款不同作用机制的生物制剂和小分子靶向药物获批 用于治疗AD，包括JAK、IL-4R、IL-13等靶点。 小分子JAK抑制剂疗效优异，但存在潜在安全性问题，TYK2有望成为小分子新选择 智通财经APP获悉，国金证券发布研报称，AD赛道市场潜力巨大，看好未来AD领域小分子及生物制剂 药物的发展。现有疗法中，小分子JAK疗效好但安全性不佳;生物制剂中，IL-4Rα等单抗安全性较好但 疗效不及JAK抑制剂。长期来看，现有疗法在安全性和疗效上仍有一定优化空间，双抗/多抗或有望融 合不同靶点的优势，有望成为更具潜力的新兴疗法。 国金证券主要观点如下： 特应性皮炎以瘙痒作为重要标志，患者人群众多，疾病负担较重 特应性皮炎(AD)是一种慢性、复发性、炎症性皮肤病，其特点为：反复发作、病程迁延，患者往往有 剧烈瘙痒。影响日常生活，患者就诊意愿强烈，亟需疗效优异、安全性良好的药物。AD患者人数众 多，全球约6~7亿患者、国内约6700万患者，未满足需求巨大。 近年来小分子和生物制剂逐步上市， ...

截至6月30日，京新药业股东户数2.57万，较上期减少0.11%；人均流通股28196股，较上期增加0.11%。 2025年1月-6月，京新药业实现营业收入20.17亿元，同比减少6.20%；归母净利润3.88亿元，同比减少 3.54%。 今年以来京新药业已经1次登上龙虎榜，最近一次登上龙虎榜为7月4日，当日龙虎榜净买入1.11亿元； 买入总计2.59亿元 ，占总成交额比21.90%；卖出总计1.48亿元 ，占总成交额比12.49%。 资料显示，浙江京新药业股份有限公司位于浙江省新昌县羽林街道新昌大道东路800号，成立日期1999 年2月13日，上市日期2004年7月15日，公司主营业务涉及化学制剂、传统中药、生物制剂、化学原料 药、医疗器械的研发、生产及销售。主营业务收入构成为：医药制造82.46%，医用器械17.54%。 京新药业所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：阿尔茨海默、仿制药、 眼科概念、抗癌治癌、生物医药等。 9月12日，京新药业盘中上涨2.02%，截至13:39，报19.70元/股，成交2.67亿元，换手率1.91%，总市值 169.62亿元。 资金流向方面，主力资 ...

Group 1 - The core point of the article is that 特宝生物 (Tebao Biotech) held its 11th meeting of the 9th Board of Directors on September 4, 2025, to discuss the proposal for granting reserved restricted stocks under the 2024 restricted stock incentive plan [1] - For the year 2024, the revenue composition of 特宝生物 indicates that 99.73% comes from biopharmaceuticals, while other businesses account for only 0.27% [1] - As of the time of reporting, 特宝生物 has a market capitalization of 34.5 billion yuan [1] Group 2 - The article also mentions 海底捞 (Haidilao) and its various ventures, highlighting that the survival rate of its sub-brands is less than 50% [1]

Core Viewpoint - Reap Bio has shown a mixed performance in stock price, with a year-to-date increase of 20.43% but a recent decline of 2.11% over the last five trading days [2] Company Overview - Reap Bio, established on August 2, 2001, and listed on September 17, 2010, is located in Tianjin Free Trade Zone and specializes in veterinary biological products, chemical drugs, biological agents, and animal health products [2] - The company's main revenue sources are: poultry biological products (35.04%), formulations and raw materials (33.24%), pet supply chain (20.63%), livestock biological products (6.86%), and others [2] Financial Performance - For the first half of 2025, Reap Bio achieved a revenue of 1.708 billion yuan, representing a year-on-year growth of 55.37%, and a net profit attributable to shareholders of 257 million yuan, up 61.19% [2] - Since its A-share listing, the company has distributed a total of 1.371 billion yuan in dividends, with 462 million yuan in the last three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders stood at 27,000, with an average of 12,406 circulating shares per person [2] - Major shareholders include Hong Kong Central Clearing Limited and Guotai CSI Livestock Breeding ETF, with notable changes in their holdings [3]

9月3日，记者从杭州城市管理部门了解到，全市城市河道沿河区域灭蚊专项行动已经陆续展开。 本次行动覆盖514条城市河道，如何将对市民的影响降到最低？答案藏在精妙的"时间管理大 法"中。据了解，所有消杀作业被严格安排在清晨8时至9时及下午4时至5时这两个人流相对较少的时 段。作业前，养护人员会提前在沿线发布通知、设置温馨提示，方便晨练、晚走的市民及时调整路线。 与过去一消杀就药味弥漫不同，今年的灭蚊行动"存在感"极低,河道边几乎闻不到味道, 这得益于药 剂的全面升级:城管部门采用高效环保的生物制剂和颗粒药物，对人类、宠物、鱼类及水生植物均安全 无害。同时，作业方式变"大水漫灌"为"超低容量喷雾" ，药剂用量减少、雾滴更细，效果更集中，气 味残留时间极短。 作业期间，城管河道养护人员还会变身"科普员"，在河边设立临时宣传点，不仅免费发放环保驱蚊 贴，更会现场开起"微课堂"，向居民科普灭蚊防控知识，提醒居民清除家中积水，从源头阻断蚊虫繁 殖。 "此次以'最小干扰'求'最大成效'的灭蚊模式是遵循城市精细化治理的又一次主动实践。"杭州市水 设施河道中心相关负责人介绍，未来，杭州市管理部门将建立长效管理机制，定期开展环境整 ...

Group 1 - The total external guarantees provided by the company and its subsidiaries amount to approximately 1.656 billion yuan, which represents 30.72% of the audited net assets attributable to ordinary shareholders for the year 2024 [1] - The company has provided guarantees totaling about 1.566 billion yuan for its subsidiaries, accounting for 29.05% of the audited net assets attributable to ordinary shareholders for 2024 [1] - The amount of guarantees for entities outside the consolidated financial statements is 90 million yuan, which is 1.67% of the audited net assets attributable to ordinary shareholders for 2024 [1] Group 2 - For the first half of 2025, the revenue composition of the company is as follows: chemical preparations account for 42.67%, chemical raw materials account for 25.02%, biological preparations account for 16.71%, pharmaceutical and other logistics trade account for 6.76%, and pharmaceutical intermediates account for 6.47% [1] - The current market capitalization of the company is 10.7 billion yuan [1]

Group 1: Recent IPOs - Agricultural B2B e-commerce platform Yimuyuan officially listed on NASDAQ, raising approximately $20.54 million by issuing 5.01 million shares, with a market capitalization of $255 million [1] - Silicon carbide substrate manufacturer Tianyue Advanced completed its listing on the Hong Kong Stock Exchange, raising about HKD 2.044 billion by issuing 47.74 million shares, with a market capitalization of HKD 20.636 billion [2] - English education institution Monkey Tree submitted an IPO application to the SEC for NASDAQ listing, planning to issue 1.6 million shares to raise approximately $7 million [3] - New energy technology company EcoFusion filed for an IPO with the SEC, planning to issue 1.5 million shares to raise $6 million [4] - Marketing company AM PM Group submitted an IPO application to the SEC for NASDAQ listing, planning to issue 1.5 million shares to raise approximately $7 million [5] - Logistics solution provider Smart Logistics filed for an IPO with the SEC, planning to issue 1 million shares with a fundraising range of $5-6 million [6] - Hong Kong brokerage Huanbo Capital submitted an IPO application to the SEC for NASDAQ listing, planning to issue 1.4 million shares to raise $6 million [8] - Software development service provider Yihua Box filed for an IPO with the SEC, planning to issue 1.5 million shares with a fundraising range of $6-7.5 million [9] - Consumer goods supplier Aigou Holdings submitted an IPO application to the SEC for NASDAQ listing, planning to issue 2 million shares to raise approximately $10 million [10] Group 2: Upcoming IPOs - AI infrastructure software provider StarRing Technology submitted an application for "A+H" share listing on the Hong Kong Stock Exchange, focusing on AI and big data infrastructure software [11] - Precision manufacturing innovation technology company Luxshare Precision submitted an application for "A+H" share listing on the Hong Kong Stock Exchange, providing integrated manufacturing solutions for various sectors [12] - Photovoltaic cell manufacturer Yingfa Ruineng filed for an IPO on the Hong Kong Stock Exchange, recognized as the third-largest N-type TOPCon cell manufacturer globally with a market share of 14.7% [13] - Intelligent cockpit solution provider Zebra Smart submitted an application for IPO on the Hong Kong Stock Exchange, focusing on developing intelligent cockpit solutions [14] - AI and high-performance computing PCB supplier Shenghong Technology submitted an application for "A+H" share listing on the Hong Kong Stock Exchange, leading the market in AI and high-performance computing PCB revenue [15] - Biopharmaceutical company Tianchen Biotech filed for an IPO on the Hong Kong Stock Exchange, focusing on the development of biological products for allergic and autoimmune diseases [16] Group 3: Ongoing IPO Processes - AIDC supporting energy storage company Shuangdeng Group is in the process of an IPO, planning to issue 58.557 million shares to raise approximately HKD 850 million, expected to list on August 26 [17] - Tungsten mining company Jiaxin International is undergoing an IPO process, planning to issue 109.8 million shares to raise approximately HKD 1.088 billion, expected to list on August 28 [17]

Core Viewpoint - Tonghe Pharmaceutical's investment in Hangzhou Boya Biopharmaceutical Co., Ltd. focuses on the development and production of long-acting complex formulations, but it is not classified as an innovative drug company [1] Company Information - Hangzhou Boya was established in 2023 and is based in Hangzhou, specializing in long-acting complex formulations [1] - The core team of Hangzhou Boya is led by Dr. Xia Jinqiang, who has over 30 years of experience in drug development and has held senior positions in major pharmaceutical companies [1] - Dr. Xia's credentials include a postdoctoral fellowship at Cornell University and a Ph.D. from Texas A&M University, along with a master's degree in analytical chemistry from the Dalian Institute of Chemical Physics [1] Research Focus - Hangzhou Boya's research is concentrated on complex dosage forms such as microsphere injectables, oral dissolving films, and biopharmaceuticals [1]

Group 1 - The revenue composition of North China Pharmaceutical for the year 2024 is as follows: chemical preparations account for 44.02%, chemical raw materials account for 26.72%, biological preparations account for 16.36%, pharmaceutical intermediates account for 6.23%, and pharmaceutical and other logistics trade account for 4.61% [1] Group 2 - As of the announcement date, the total external guarantees provided by North China Pharmaceutical and its subsidiaries amount to approximately 1.757 billion yuan, which represents 32.6% of the audited net assets attributable to ordinary shareholders for the year 2024 [3] - The company has provided guarantees totaling approximately 1.667 billion yuan for its subsidiaries, accounting for 30.93% of the audited net assets attributable to ordinary shareholders for the year 2024 [3] - The amount of guarantees provided to entities outside the consolidated financial statements is 90 million yuan, which is 1.67% of the audited net assets attributable to ordinary shareholders for the year 2024 [3]